New oncology drugs have, for decades, followed a well-trodden path of sequential clinical trials to get from the laboratory to the patient. This model has proven its worth by delivering […] Read more
Tobacco smoking dramatically increases the risk of developing lung cancers, and it has long been recognized that nicotine addiction is one of the biggest obstacles to changing current smokers’ behavior. […] Read more
By Erik J. MacLaren, PhD The pan-ErbB inhibitor afatinib (Gilotrif) improves progression-free survival (PFS), time-to-treatment-failure (TTF) rate, and objective response rate (ORR) compared to the first-generation EGFR inhibitor gefitinib (Iressa) […] Read more
The International Association for the Study of Lung Cancer (IASLC) and the Oncology Unit of the 3rd Department of Medicine, Medical School of Athens, “Sotiria” Hospital, Greece organized and hosted […] Read more
By Erik J. Mac Laren, PhD In 2015, the US Food and Drug Administration (FDA) approved an unprecedented 7 new drugs or new uses for drugs for patients with lung […] Read more
By Erik J. Mac Laren, PhD In late 2015, the US National Cancer Institute (NCI) Thoracic Malignancy Steering Committee (TMSC) published its strategic priorities for the coming years. These include: […] Read more
By Professor John K. Field MA, PhD, BDS, FRCPath The advent of lung cancer computed tomography (CT) screening was initiated by the Early Lung Cancer Action Project (ELCAP) group in […] Read more
By Emily Stone, MBBS, MMed, FRACP, and Graham Warren, MD, PhD Tobacco control is set to become one of the most clinically effective and rapidly developing areas in lung cancer […] Read more
By Nicola M. Parry, DVM Lung cancer survivor Kathy Weber is an ardent ambassador for the International Association for the Study of Lung Cancer (IASLC). “My involvement with the IASLC […] Read more
By Lori Alexander, MTPW, ELS, MWC How does a person with stage IV lung cancer live a meaningful life? That’s the question Paul Kalanithi explores in When Breath Becomes Air, […] Read more